India-based pharmaceutical company Intas Pharmaceuticals, in collaboration with its global subsidiaries operating under the Accord brand, announced on Thursday that it has enhanced its global position as a leading supplier of pegfilgrastim following the successful acquisition of UDENYCA (pegfilgrastim-cbqv) from Coherus BioSciences Inc.

UDENYCA, a biosimilar to Neulasta (pegfilgrastim), expands Intas and Accord's FDA-approved biosimilar portfolio.

With this acquisition, Accord BioPharma, Intas' US specialty business, continues the commercialisation of UDENYCA to decrease the incidence of infection, as manifested by febrile neutropenia, in patients with non-myeloid malignancies receiving myelosuppressive anti-cancer drugs associated with a clinically significant incidence of febrile neutropenia.

The acquisition also brings talent from Coherus BioSciences. Key Coherus employees across multiple functions, including Sales, Marketing, Finance, Supply Chain, and Quality and Manufacturing have joined Accord BioPharma.